|
CREB3L2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.02120001344019E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.1599999566746E-09 |
| Normal-vs-Stage2 |
1.71739999998977E-07 |
| Normal-vs-Stage3 |
2.06439976224715E-10 |
| Normal-vs-Stage4 |
3.52679996318273E-10 |
| Stage1-vs-Stage2 |
5.590800E-01 |
| Stage1-vs-Stage3 |
1.403400E-01 |
| Stage1-vs-Stage4 |
1.343170E-01 |
| Stage2-vs-Stage3 |
1.362640E-01 |
| Stage2-vs-Stage4 |
1.336600E-01 |
| Stage3-vs-Stage4 |
7.091400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.39910022140577E-10 |
| Normal-vs-AfricanAmerican |
2.020800E-03 |
| Normal-vs-Asian |
3.32469607400299E-11 |
| Caucasian-vs-AfricanAmerican |
2.380200E-01 |
| Caucasian-vs-Asian |
5.815600E-02 |
| AfricanAmerican-vs-Asian |
5.998300E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.33340022251605E-10 |
| Normal-vs-Female |
1.98469995993378E-09 |
| Male-vs-Female |
2.237200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.79839998448728E-09 |
| Normal-vs-Age(41-60Yrs) |
1.0949999795784E-09 |
| Normal-vs-Age(61-80Yrs) |
4.40229996900854E-09 |
| Normal-vs-Age(81-100Yrs) |
2.479900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.780600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.647200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.189600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.598200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.158400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.087200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.926080E-02 |
| Classical-VS-Follicular |
4.444600E-01 |
| Classical-VS-Other |
1.796830E-01 |
| Classical-VS-Normal |
3.54800000490485E-09 |
| Tall-VS-Follicular |
1.630010E-02 |
| Tall-VS-Other |
5.075400E-01 |
| Tall-VS-Normal |
7.83789699809745E-11 |
| Follicular-VS-Other |
1.600380E-01 |
| Follicular-VS-Normal |
5.71749999567217E-08 |
| Other-VS-Normal |
3.95679999987131E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.75509973010924E-10 |
| Normal-vs-N1 |
7.17189974075438E-10 |
| N0-vs-N1 |
4.508400E-01 |
|
|
